Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
The 12-hour relief claim is qualified by patient results and a separate four-dose-daily lubrication finding.
- Formulated with hyaluronic acid, Systane® PRO PRESERVATIVE-FREE instantly hydrates dry eyes1
- Systane® PRO PF is a multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes2-4
-
The latest addition to the #1 global consumer brand of artificial tears5 is now available in
Canada

Introducing Systane® PRO Preservative-Free (PF) in
Dry eye disease (DED) is one of the most common ocular surface disorders, affecting an estimated 6 million people in
“At Alcon, we are committed to ensuring that dry eye sufferers can get the relief they deserve, which is why we are proud to unveil Systane PRO PF, the longest lasting dry eye symptom relief eye drop in the Systane portfolio,” said Vanessa Johari Hansen, Country Franchise Head, Vision Care, Alcon Canada.2 “Systane PRO’s PF formula works to provide sustained hydration, restore tear film stability, and protect against further irritation of dry eyes.”3-4
Patients with dry eyes often experience symptoms when moisture retention and tear stability are impacted by a variety of factors, including aging, environment, and digital device use.10 Combatting these everyday challenges, this new formula covers the surface of the eye for instant hydration and soothing dry eye relief, protects from and prevents further dryness of the eye with long-lasting lubrication,** and stabilizes the tear film to prevent from further evaporation.2-4^
“I have witnessed firsthand how disruptive, and at times debilitating, dry eye symptoms can be,” said Dr. François Piuze, optometrist and co-owner of the Eye Am clinics in
As part of Alcon’s ongoing efforts to educate audiences around the effects and treatment of DED, the organization recently partnered with the Tear Film & Ocular Surface Society (TFOS) to develop the DEWS III report, building upon the globally recognized body of work that has helped shape clinical understanding of DED. “The report highlights the multifactorial and symptomatic nature of the disease and the importance of providing personalized treatment strategies,” notes Dr. Piuze. “This includes first-line foundational treatment options with ingredients like HP-guar and hyaluronic acid (HA), based on individual patient risk factors and disease subtypes.”
To learn more about Systane PRO PF, please visit https://systane.myalcon.com/en-ca/products/systane-pro-preservative-free/
Important Information for the Systane® Family of Products
Systane lubricant eye drops have been clinically proven to reduce the symptoms of dry eye, providing fast, long-lasting relief and comfort. Systane is the #1 global consumer brand of artificial tears.5 Systane® COMPLETE provides symptom relief for people who suffer from evaporative dry eye, aqueous tear-deficient dry eye or mixed dry eye. Systane® ULTRA is designed for dry eye with aqueous deficient patients. Systane® BALANCE lubricant eye drops are designed specifically for patients with evaporative dry eye associated with meibomian gland dysfunction. Systane® HYDRATION gives long-lasting relief of dry eye symptoms for moderate or chronic sufferers or patients who are recovering from corneal or other eye surgery.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals, and programs that advance access to quality eye care. Learn more at www.alcon.com.
*
**Dose: 4 times a day.
^Improvement in NITBUT demonstrated at Day 30 compared to baseline. Dosed 4 times a day. N =316; (p<0.0001).
References
- Alcon data on file, 2025. REF-26802.
- SYSTANE Hydration (HA/HPG) provided effective hydration and lubrication and demonstrated prolonged retention of effect. (p.1).
- Rangarajan R, Ketelson H. Preclinical evaluation of a new hydroxypropyl-guar phospholipid nanoemulsion-based artificial tear formulation in models of corneal epithelium. J Ocul Pharmacol Ther. 2019;35(1):32-37. doi:10.1089/jop.2018.0031.
- Craig JP, Muntz A, Wang MTM, Luensmann D, Tan J, Trave Huarte S, Xue AL, Jones L, Willcox MDP, Wolffsohn JS. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. Ocul Surf. 2021 Apr;20:62-69. doi: 10.1016/j.jtos.2020.12.006. Epub 2021 Jan 2. PMID: 33401019.
- Alcon data on file, 2025. REF-26802.
- Caffery B, Srinivasan S, Reaume CJ, Fischer A, Cappadocia D, Siffel C, Chan CC. Prevalence of dry eye disease in Ontario, Canada: A population-based survey. Ocul Surf. 2019 Jul;17(3):526-531. doi: 10.1016/j.jtos.2019.02.011. Epub 2019 Feb 27. PMID: 30825521.
- Kesavan S, Prud’homme RK. Rheology of guar and (hydroxypropyl) guar crosslinked by borate. Macromolecules. 1992;25(7):2026-2032.doi:10.1021/ma00033a029.
- Ubels JL, Clousing DP, Van TA, et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropylguar as a gelling agent. Curr Eye Res. 2004;28(6):437-444. doi:10.1080/02713680490503787.
- Rangarajan R, Kraybill B, Ogundele A, Ketelson HA. Effects of a hyaluronic acid/hydroxypropyl guar artificial tear solution on protection, recovery, and lubricity in models of corneal epithelium. J Ocul Pharmacol Ther. 2015;31(8):491-497. doi:10.1089/jop.2014.0164.
- Market Scope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. St. Louis, MO.
Connect with us on
Facebook
LinkedIn
©2026 Alcon Inc. CA-SAF-2600098
View source version on businesswire.com: https://www.businesswire.com/news/home/20260928269219/en/
Media Relations
Tenney Loweth (Weber Shandwick for Alcon Canada)
647-782-5094
tenney.loweth@omc.com
Luiza Barros (Alcon)
+1 (817)-751-6658
luiza.barros@alcon.com
Investor Relations
Daniel Cravens, Richard Bourne
+ 41 589 112 110 (Geneva)
+ 1 817 615 2789 (Fort Worth)
Investor.relations@alcon.com
Source: Alcon Inc.